Cerdulatinib for treating myeloma
Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.
1. A method of treating acute myeloid leukemia (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the effective amount is from about 30 mg to about 80 mg daily and administration is twice daily, wherein the patient has an FGFR3 activation mutation.
2. The method of claim 1 , wherein the patient is not being treated with fludarabine.
3. The method of claim 1 , wherein the patient is not being treated with a purine analog.
4. The method of claim 1 , wherein the patient is not being treated with an agent that interferes with DNA synthesis.
5. The method of claim 1 , wherein the effective amount is about 15 mg, 20 mg, 25 mg, 30 mg, or 35 mg twice daily.
6. The method of claim 1 , wherein the patient suffers from an advanced malignancy of AML or MPD.
7. The method of claim 1 , wherein the patient has an albumin level lower than 3.5 mg/dL.
8. The method of claim 1 , wherein the patient has a B2-microglobulin level from 3.5 to 5 mg/L or greater than 5 mg/L.
9. The method of claim 1 , further comprising administering to the patient a second agent.
10. The method of claim 9 , wherein the second agent is a P90RSK inhibitor.
11. The method of claim 9 , wherein the second agent is selected from the group consisting of dexamethasone, melphalan, doxorubicin, bortezomib, lenalidomide, prednisone, carmustine, etoposide, cisplatin, vincristine, cyclophosphamide, BI-D1870, and thalidomide.
12. A method of treating acute myeloid leukemia (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the effective amount is from about 30 mg to about 80 mg daily and administration is twice daily, wherein the patient has relapsed or not responded to a prior chemotherapy, wherein the patient has failed at least two prior therapies.
13. The method of claim 12 , wherein the patient is not being treated with fludarabine.
14. The method of claim 12 , wherein the patient is not being treated with a purine analog.
15. The method of claim 12 , wherein the patient is not being treated with an agent that interferes with DNA synthesis.
16. The method of claim 12 , wherein the effective amount is about 15 mg, 20 mg, 25 mg, 30 mg, or 35 mg twice daily.
17. The method of claim 12 , wherein the patient suffers from an advanced malignancy of AML or MPD.
18. The method of claim 12 , wherein the patient has an albumin level lower than 3.5 mg/dL.
19. The method of claim 12 , wherein the patient has a B2-microglobulin level from 3.5 to 5 mg/L or greater than 5 mg/L.
20. The method of claim 12 , further comprising administering to the patient a second agent.
21. The method of claim 20 , wherein the second agent is a P90RSK inhibitor.
22. The method of claim 20 , wherein the second agent is selected from the group consisting of dexamethasone, melphalan, doxorubicin, bortezomib, lenalidomide, prednisone, carmustine, etoposide, cisplatin, vincristine, cyclophosphamide, BI-D1870, and thalidomide.